Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

503614-92-4Apixaban Carboxylic Acid Impurity

● In Stock

Catalogue No.:	VL3170001
CAS No.:	503614-92-4
Mol. Formula:	C25H24N4O5
Mol. Weight:	460.48 g/mol

How can we help?

Add to RFQ list

Additional information on CAS 503614-92-4

Parent drug

Apixaban

IUPAC Name

4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl) phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid

Pharmacopeial Synonyms

N/A

Synonyms

Apixaban Acid Impurity; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylic acid

Smiles

O=C(C1=NN(C2=CC=C(OC)C=C2)C3=C1CCN(C4=CC=C(N5C(CCCC5)=O)C=C4)C3=O)O

InChI

InChI=1S/C25H24N4O5/c1-34-19-11-9-18(10-12-19)29-23-20(22(26-29)25(32)33)13-15-28(24(23)31)17-7-5-16(6-8-17)27-14-3-2-4-21(27)30/h5-12H,2-4,13-15H2,1H3,(H,32,33)

Shipping Condition

Ambient Temperature

Description

Apixaban Carboxylic Acid Impurity, CAS 503614-92-4, is a structurally defined process- or degradation-related impurity of the factor Xa inhibitor apixaban, corresponding to 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylic acid. With molecular formula C25H24N4O5 and molecular weight 460.48 g/mol, it represents the carboxylic acid analogue at the heteroaromatic core. Formation may arise from hydrolytic or synthetic side reactions during elaboration of the pyrazolopyridine scaffold. Because it is a non-volatile, polar, aromatized impurity, characterization typically relies on LC-MS/MS, high-resolution MS, and orthogonal HPLC-UV methods, with impurity profiling guided by ICH Q3A/Q3B principles.

References

Budovich, Aliaksandr, et al. “Role of Apixaban (Eliquis) in the Treatment and Prevention of Thromboembolic Disease.” Pharmacy and Therapeutics, vol. 38, no. 4, 1 Apr. 2013, pp. 206–231, www.ncbi.nlm.nih.gov/pmc/articles/PMC3684191/#b5-ptj3804206. Accessed 24 Jan. 2022.